- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Analyzing AMD in research, COVID-19-era practice
Mary Elizabeth Hartnett, MD, FACS, FARVO, and Mark Breazzano, MD, discuss current research being conducted involving AMD and maximizing patient outcomes amid the pandemic.
Mary Elizabeth Hartnett, MD, FACS, FARVO, a distinguished professor in Ophthalmology and Visual Sciences, University of Utah, as well as director of Pediatric Retina at the John A. Moran Eye Center, and Mark Breazzano, MD, a vitreous and retinal surgeon at the Wilmer Eye Institute, Johns Hopkins University, analyze two areas of age-related macular degeneration (AMD) relevant to today's field:
Dr. Hartnett highlights current research being conducted on the pathophysiology of AMD involving very long chain polyunsaturated fatty acids and new mechanism for fibrosis and neovascular AMD.
Dr. Breazzano discusses how the COVID-19 pandemic has altered how ophthalmologists treat wet AMD, and how physicians can maximize their patient outcomes.
